<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946373</url>
  </required_header>
  <id_info>
    <org_study_id>MAT-02</org_study_id>
    <secondary_id>2012-000450-63</secondary_id>
    <nct_id>NCT01946373</nct_id>
  </id_info>
  <brief_title>T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma</brief_title>
  <official_title>A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if dendritic cell vaccine will increase the effect of&#xD;
      tumor infiltrating lymphocytes given with chemotherapy and interleukin-2 in patients with&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MAT02 clinical trial is a phase 1 clinical trial with the objective to assess the safety,&#xD;
      feasibility and immunological efficacy of the combined application of two immunological&#xD;
      treatment modalities in patients with metastatic melanoma:&#xD;
&#xD;
        1. Cohort A: After a non-myeloablative conditioning regimen, 5 patients will receive one&#xD;
           bulk infusion of T cells. T cells will be expanded ex vivo from autologous tumor&#xD;
           infiltrating lymphocytes (TIL). In vivo persistence of the infused cells will be&#xD;
           supported by administration of IL-2, a T cell survival factor.&#xD;
&#xD;
        2. Cohort B: This adoptive cell transfer (ACT) step will in additional 10 patients be&#xD;
           followed by a vaccination with autologous, in vitro-generated, dendritic cells (DC),&#xD;
           loaded with autologous tumor lysate and a synthetically produced peptide derived from&#xD;
           the tumor associated antigen NY-ESO 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the T cell therapy, with and without dendritic cell vaccine, as evaluated according to the NCI CTCAE scale version 4.0</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + T cells + IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + T cells + IL-2 + DCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Chemotherapy + T cells + IL-2</arm_group_label>
    <arm_group_label>Chemotherapy + T cells + IL-2 + DCV</arm_group_label>
    <other_name>Sendoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Chemotherapy + T cells + IL-2</arm_group_label>
    <arm_group_label>Chemotherapy + T cells + IL-2 + DCV</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T cells</intervention_name>
    <arm_group_label>Chemotherapy + T cells + IL-2</arm_group_label>
    <arm_group_label>Chemotherapy + T cells + IL-2 + DCV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <arm_group_label>Chemotherapy + T cells + IL-2</arm_group_label>
    <arm_group_label>Chemotherapy + T cells + IL-2 + DCV</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cell vaccine</intervention_name>
    <arm_group_label>Chemotherapy + T cells + IL-2 + DCV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with measurable (direct on body surface or by x-ray and/or CT) malignant&#xD;
             melanoma (including uveal melanoma), that is advanced, inoperable stage III (advanced&#xD;
             regional lymph node metastases, or more than 5 in-transit metastases, N2) or stage IV&#xD;
             (distant metastasis, M1) according to the AJCC classification and confirmed by&#xD;
             histology/cytology and appropriate radiological investigations.&#xD;
&#xD;
          -  Patients with a palpable resectable lesion located in the skin or in a lymph node or a&#xD;
             lesion accessible by (core) biopsy.&#xD;
&#xD;
          -  Disease should be in progression and the patient should have exhausted other approved&#xD;
             therapeutic options, if not the physician considers that an earlier study entry&#xD;
             benefits the patient.&#xD;
&#xD;
          -  Ambulatory performance status (ECOG 0, 1, 2).&#xD;
&#xD;
          -  Age 18-74 and life expectancy greater than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the above criteria are not met.&#xD;
&#xD;
          -  Significant history or current evidence of cardiovascular disease (e.g. uncontrolled&#xD;
             congestive heart failure or hypertension, unstable coronary artery disease or serious&#xD;
             arrhythmias) or major respiratory diseases. In questionable cases, a stress test&#xD;
             should be performed.&#xD;
&#xD;
          -  Recipients of a major organ allograft. Autoimmune diseases such as, but not limited&#xD;
             to, inflammatory bowel disease or multiple sclerosis. Vitiligo is not an exclusion&#xD;
             criterion. Other serious chronic diseases.&#xD;
&#xD;
          -  Other serious illnesses, e.g. active infections requiring antibiotics, bleeding&#xD;
             disorders.&#xD;
&#xD;
          -  Has had prior systemic cancer therapy within the past four weeks at the time of the&#xD;
             start of the lymphodepletion regimen.&#xD;
&#xD;
          -  Patients diagnosed with prior malignancies (except adequately treated basal cell&#xD;
             carcinomas of the skin or in situ carcinomas of the skin or in situ carcinomas of the&#xD;
             cervix, surgically cured) within the past 5 years.&#xD;
&#xD;
          -  Patients with second advanced malignancies concurrently.&#xD;
&#xD;
          -  Active CNS metastases. (Note: Patients with brain metastases that have been completely&#xD;
             resected at least one month prior to registration or have undergone gamma knife&#xD;
             treatment with no evidence of recurrence on CT and who are neurologically stable, are&#xD;
             not excluded).&#xD;
&#xD;
          -  Organic brain syndrome or significant psychiatric disorder which would preclude&#xD;
             participation in the full protocol and follow-up.&#xD;
&#xD;
          -  Immunodeficiency, previous splenectomy or radiation therapy of the spleen.&#xD;
&#xD;
          -  Screening laboratory values:&#xD;
&#xD;
             a) Inadequate hematologic function defined by: i) White blood count (WBC) &lt;3.0 x 109/l&#xD;
             ii) Platelet count &lt;100x109/l iii) Hemoglobin level &lt;100 g/l b) Inadequate hepatic&#xD;
             function as defined by either: i) Total bilirubin level &gt;1.5 times the upper limit of&#xD;
             normal (ULN) ii) Aspartate amino transferase (AST) or alanine amino transferase (ALT)&#xD;
             &gt;3 times the ULN (if related to liver metastases &gt;5 times the ULN) c) Inadequate renal&#xD;
             function defined as serum creatinine &gt;1.5 times the ULN&#xD;
&#xD;
          -  Infectious diseases that can be transmitted via contact with blood, such as HIV,&#xD;
             Hepatitis B and C.&#xD;
&#xD;
          -  Women who are pregnant or nursing will be excluded because of the potentially&#xD;
             dangerous effects of the preparative chemotherapy on the fetus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Wolodarski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Wolodarski, MD</last_name>
    <phone>+46851770000</phone>
    <email>maria.wolodarski@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rolf Kiessling, MD, PhD</last_name>
    <phone>+46733428848</phone>
    <email>rolf.kiessling@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Wolodarski, MD</last_name>
      <phone>+46851770000</phone>
      <email>maria.wolodarski@sll.se</email>
    </contact>
    <investigator>
      <last_name>Maria Wolodarski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Wolodarski</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Dendritic cell vaccination</keyword>
  <keyword>Lymphodepletion</keyword>
  <keyword>Adoptive cell transfer</keyword>
  <keyword>T cells</keyword>
  <keyword>Tumor infiltrating lymphocytes</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Phase I study</keyword>
  <keyword>Monocytes</keyword>
  <keyword>Autologous</keyword>
  <keyword>NY-ESO-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

